Table 8.6d

Immunosuppression Use: Antirejection Treatment from Transplant

to One Year Posttransplant, 1993 to 2002

Recipients with Kidney-Pancreas Transplants

		Year of Transplant
		1993	1994	1995	1996	1997	1998	1999	2000	2001	2002
Transplants		661	748	919	860	853	972	943	914	891	905
Tx with Antirejection Treatments		487	495	622	565	317	285	260	232	194	191
Antibodies	Category Usage	77.8%	65.9%	47.6%	31.3%	46.7%	43.9%	42.7%	41.4%	32.0%	50.8%
	ALG	24.2%	17.4%	8.4%	0.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
	ATG/NRATG/NRATS	2.1%	2.0%	6.9%	8.8%	18.3%	9.8%	6.5%	3.9%	0.5%	2.6%
	OKT3	67.1%	60.4%	41.6%	24.8%	34.7%	35.4%	25.0%	22.8%	12.4%	10.5%
	Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.3%	3.2%	16.5%	15.1%	20.6%	34.0%
	Zenapax	0.0%	0.0%	0.0%	0.0%	0.3%	1.8%	1.5%	1.7%	1.0%	4.7%
	Simulect	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	2.2%	0.5%	1.0%
	Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.5%
Corticosteroids	Category Usage	81.1%	76.4%	66.1%	54.9%	69.1%	77.5%	80.4%	82.8%	87.1%	75.9%
	Steroids	81.1%	76.4%	66.1%	54.9%	69.1%	77.5%	80.4%	82.8%	87.1%	75.9%
Antimetabolites	Category Usage	0.2%	0.0%	0.2%	0.2%	0.0%	0.7%	0.0%	0.0%	0.0%	0.0%
	Cytoxan	0.0%	0.0%	0.2%	0.2%	0.0%	0.7%	0.0%	0.0%	0.0%	0.0%
	Methotrexate	0.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 3, 2004.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may

be prescribed more than one drug within the same category.